First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal, Aurelia Alexandru, Ying Cheng, Hiroshi Sakai, Luis Paz-Ares, Shun Lu, Thomas John, Xiaowu Sun, Aniela Moisei, Fiona Taylor, Rachael Lawrance, Xiaoqing Zhang, Judi Sylvester, Yong Yuan, Steven I. Blum, John R. Penrod, David P. Carbone

Open source

DOI: 10.1016/j.ejca.2023.01.015
Published: 2023-04
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2023.01.015,
  title = {First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes},
  author = {Martin Reck and Tudor-Eliade Ciuleanu and Manuel Cobo and Michael Schenker and Bogdan Zurawski and Juliana Menezes and Eduardo Richardet and Jaafar Bennouna and Enriqueta Felip and Oscar Juan-Vidal and Aurelia Alexandru and Ying Cheng and Hiroshi Sakai and Luis Paz-Ares and Shun Lu and Thomas John and Xiaowu Sun and Aniela Moisei and Fiona Taylor and Rachael Lawrance and Xiaoqing Zhang and Judi Sylvester and Yong Yuan and Steven I. Blum and John R. Penrod and David P. Carbone},
  year = {2023},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2023.01.015},
  url = {https://doi.org/10.1016/j.ejca.2023.01.015}
}

RIS

TY  - JOUR
TI  - First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
AU  - Martin Reck
AU  - Tudor-Eliade Ciuleanu
AU  - Manuel Cobo
AU  - Michael Schenker
AU  - Bogdan Zurawski
AU  - Juliana Menezes
AU  - Eduardo Richardet
AU  - Jaafar Bennouna
AU  - Enriqueta Felip
AU  - Oscar Juan-Vidal
AU  - Aurelia Alexandru
AU  - Ying Cheng
AU  - Hiroshi Sakai
AU  - Luis Paz-Ares
AU  - Shun Lu
AU  - Thomas John
AU  - Xiaowu Sun
AU  - Aniela Moisei
AU  - Fiona Taylor
AU  - Rachael Lawrance
AU  - Xiaoqing Zhang
AU  - Judi Sylvester
AU  - Yong Yuan
AU  - Steven I. Blum
AU  - John R. Penrod
AU  - David P. Carbone
PY  - 2023
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2023.01.015
UR  - https://doi.org/10.1016/j.ejca.2023.01.015
ER  -

APA

Reck, M., Ciuleanu, T., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Cheng, Y., Sakai, H., Paz-Ares, L., Lu, S., John, T., Sun, X., Moisei, A., Taylor, F., Lawrance, R., Zhang, X., Sylvester, J., Yuan, Y., Blum, S. I., Penrod, J. R., & Carbone, D. P. (2023). First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.015

Source records

crossref · retrieved 2026-09-26T23:51:16.372Z